|
ENTERIS BIOPHARMA IS…
- A wholly owned subsidiary of SWK Holdings Corporation (NASDAQ: SWKH).
- A 32,000 sq. ft. cGMP CDMO located in northern New Jersey, USA.
- A newly renovated, state-of-the-art drug product manufacturing facility that is equipped to handle a variety of APIs including dedicated processing and containment areas for highly potent APIs.
- A CDMO offering services in pre-formulation, formulation, analytical method development and validation, quality control, quality assurance, and clinical and small-volume commercial manufacturing of Orally Inhaled and Nasal Drug Products (OINDP) and solid oral dose tablets.
|
|
|
WHO WE ARE…
- Phase 1 & 2 clinical manufacturing services to support pharma companies developing Orally Inhaled and Nasal Products (OINDP) using Aptar Pharma’s device platforms.
- Chemistry, Manufacturing and Control (CMC) experts, with a senior management team comprising over 150 years of combined experience in the pharmaceutical industry.
|
|
|
|
TECHNOLOGIES…
- OINDP manufacturing, filling, and assembly equipment for Aptar devices
- Peptelligence® Technology for OSD formulations of peptides
- Properma® for OSD formulations of BCS-III and BCS class IV molecules.
|
|
|
GOING FORWARD…
A recent change in leadership at SWKH has led to a strategic realignment. The Enteris Team has been tasked with finding a new owner for the CDMO business.
|
|
|
The following information packages are available:
· Facility Overview
· Manufacturing Equipment
· Analytical Instruments
· Peptelligence® and Properma® Formulation Technologies
|
|
|
Enteris Biopharma, Inc. Mutual Confidential Disclosure Agreement
|
|
|
Heidi Lipton
hlipton@rockcreekfa.com
Rock Creek Advisors, LLC
|
Chris Moore
cmoore@rockcreekfa.com
Rock Creek Advisors, LLC
|
Jim Skelton
jskelton@rockcreekfa.com
Rock Creek Advisors, LLC
|
|
|
|
|
|
RockCreekFA.com
Linkedin
|
|
|
|
